Cardiac ToxicityLung Cancer Stage IIILung Cancer Stage IIRadiation ToxicityCardiac Disease
Investigational drug(s) / intervention(s)
Chemoradiotherapy
Chemoradiotherapy: Cardiac Magnetic Resonance scan and ECG
Study summary
Patients with loco-regional NSCLC planned for curative treatment with chemoradiotherapy will be invited to participate in a prospective study; besides routine treatment, the patients will be followed with an ECG and cardiac MR for at least two years after radiotherapy treatment.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥ 18 Years
* Inoperable and histologically/cytologically verified NSCLC.
* Planned treatment with curative intent.
* Capable of completing study procedures ECG and Cardiac MR.
* Able of giving written and informed consent before study procedures are initiated.
Exclusion Criteria:
* Vulnerable patients.
* Patients with operable devices as pacemaker/ICD and cochlear implant or other conditions where MR scan is contraindicated.
* Claustrophobia.
Primary outcome measure(s)
Overall survival — 2 Years All cause mortality
Change in Left Ventricular Ejection Fraction — Baseline, at 6, 12 and 24 months. Change from baseline, evaluated by cardiac MR
Number of participants with treatment related adverse events and cardiac disease after radiotherapy as assesed by CTCAE v4.0. — 2 years. Assesed by patient interview and review of medical record.
Cardiovascular specific mortality — 2 years. Assesed by patient interview and review of medical record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
